News Contact Us Careers Get E-Mail alerts Search

ADMA Biologics, Inc.

  • Home
  • About Us
    • About ADMA Biologics
    • What We Do
    • Who We Are
      • Senior Leadership Team
      • Board of Directors
      • Scientific Advisory Board
      • Compliance
  • Our Products
    • Products Overview
    • About Primary Immunodeficiency Disease (PI)
    • ASCENIV™
    • BIVIGAM®
    • Nabi-HB®
  • Manufacturing
    • Our Patented Process
    • Contract Manufacturing and Aseptic Fill-Finish
  • Plasma & IVIG
    • What Is Plasma?
    • Immune Globulin's Critical Role
    • Immune Globulin Production
  • Medical Affairs
    • Medical Affairs Overview
    • Publications
  • ADMA BioCenters
  • Investors
    • Overview
    • Press Releases
      • Email Alerts
    • Company Info
      • Profile
      • Presentation
      • Management Team
      • Contacts
      • FAQs
    • Analyst Coverage
    • Events & Webcasts
    • Financial Info
      • Financial Results
      • Balance Sheet
      • Income Statement
      • Cash Flow
      • Annual Reports
    • Stock Info
      • Stock Data & Quote
      • Charts
      • Historical Data
    • SEC Filings
      • SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Governance
      • Board of Directors
      • Board Committees
      • Documents
  • News
  • Contact Us
  • Careers
  • Get E-Mail alerts
  • Search

You are now leaving www.admabiologics.com

The link you have selected will take you outside of ADMA Biologics corporate website. The site you will be entering is intended for U.S. audiences only. Do you wish to continue?

Yes No

News

Investors

Investors

  • Overview
  • Press Releases
    • Email Alerts
  • Company Info
    • Profile
    • Presentation
    • Management Team
    • Contacts
    • FAQs
  • Analyst Coverage
  • Events & Webcasts
  • Financial Info
    • Financial Results
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Annual Reports
  • Stock Info
    • Stock Data & Quote
    • Charts
    • Historical Data
  • SEC Filings
    • SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Documents
  • Press Releases

  • Email Alerts

Click below for current and archived news related to the company.

ADMA Biologics Announces Pricing of Upsized $82.3 Million Public Offering of Common Stock
Feb 06, 2020 8:40pm EST
ADMA Biologics Announces Proposed $75 Million Public Offering of Common Stock
Feb 06, 2020 4:06pm EST
ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2019 Revenues and Provides 2020 Strategic Outlook
Jan 09, 2020 7:00am EST
ADMA Biologics Enters Into a Manufacturing and Supply Agreement to Produce and Sell Plasma-Derived Intermediate Fractions
Jan 07, 2020 7:00am EST
ADMA Biologics Added to NASDAQ Biotechnology Index
Dec 17, 2019 7:08am EST
ADMA Biologics to Present at Jefferies 2019 London Healthcare Conference
Nov 13, 2019 7:08am EST
ADMA Biologics Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress
Nov 06, 2019 5:02pm EST
ADMA Biologics Announces Acceptance to the Plasma Protein Therapeutics Association
Nov 04, 2019 7:08am EST
ADMA Biologics Named Company of the Year by BioFlorida
Oct 22, 2019 7:48am EDT
ADMA Biologics Announces First Commercial Sales of ASCENIV™
Oct 21, 2019 7:48am EDT
  • Prev
  • 1...
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • ...25
  • Next
ADMA Biologics, Inc.
Twitter logo
LinkedIn logo
About Us Our Products Manufacturing Plasma & IVIG Medical Affairs Investors HCP Disclosure Reporting Privacy Policy Disclaimer Sitemap Contact Us Connect with Us Email Alerts RSS
Best places to work
Bio NJ

2020 Innovator Award

50 fastest companies
2022 Fast 500 Deloitte
Bio Florida

Named 2019 Company of the Year

© Copyright 2023 ADMA Biologics, Inc.
Ramsey, NJ Offices 201-478-5552
Boca Raton, FL Offices 561-989-5800
info@admabio.com